News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Migami, Inc. Continues Implementation of Acquisition Strategy regarding Various Proprietary Drug-Delivery Platforms and CMG Manufacturing Facilities


3/26/2009 9:35:08 AM

WOODLAND HILLS, Calif.--(BUSINESS WIRE)--Migami, Inc, a publicly traded pharmaceutical and cosmeceutical company (symbol: MIGA) located in Woodland Hills, CA, (“Migami”) is negotiating a Letter of Intent (“LOI”) regarding an Asset Purchase Agreement with respect to Migami’s proposed acquisition of a patented, liposomal drug-delivery platform and certain related manufacturing assets. The liposomal drug-delivery platform being acquired is considered by many to be the next evolutionary step in liposomal technology.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES